Sentences with phrase «in on cancer cells»

«Not only does I124 - chlor home in on cancer cells; it also can deliver physical damage.»

The sponge is implanted under the skin, and is designed to recruit and reprogram a patient's own immune cells «on site,» instructing them to travel through the body, home in on cancer cells, then kill them.

Three new studies suggest ways to home in on cancer cells during treatment, leaving surrounding healthy tissue unharmed.

This ability to isolate, culture and grow the cancer cells will allow researchers to zero in on the cancer cells that matter to the health of the patient.

The targeted viruses «have the potential to add a new tool to our arsenal,» he says, because they home in on cancer cells more aggressively.

Not exact matches

Weeks later, Yee realized that he didn't have the equipment he needed to pluck out of Ziskin's blood the rare (perhaps one in 100,000) T cells that could identify the subtle peptide markers on the surface of her cancer cells and attack the disease.

Basically, CAR - T therapy involves taking a patient's own immune «killer» T - cells, inserting new genetic code into those cells which turn them into cancer - hunters that can home in on malignant B - cells (another kind of immune cell), and then pumping these specialized leukemia - busting cells back into the patient.

The medicines, which help unleash the immune system on cancer cells, were tested in patients with advanced lung cancer.

Researchers from the Sichuan University in Chengdu inserted the re-engineered cells into a lung cancer patient participating in a clinical trial at the West China Hospital on October 28th, according to Nature.

Hoping to learn something about how the human body defends itself against cancer, he had zeroed in on a complex regiment of lymphocytes called T cells, common to the immune systems in both mouse and man.

This new kind of approach to fighting blood cancers is truly personalized; immune T - cells are extracted from patients, genetically tinkered to home in on an destroy cancerous cells, multiplied in a lab, and then jolted back into the patient's body within about two weeks.

BioNTech, which has around 700 employees at sites in Germany — more than any other unlisted biotech firm in Europe — is also working on other cancer - fighting technologies, including antibodies, cell therapies and small molecules.

Investigators have repeatedly touted the drug as a potential lynchpin in immuno - oncology, focusing on an enzyme that suppresses the immune cells Opdivo and a whole new class of PD - 1 / L1 checkpoints are designed to unleash in an attack on cancer cells.

I mean, if god wants him to live he wouldn't have given him cancer in the first place but lets just say he contr.acted can.cer on his own but was called upon god to do these good dee.ds but needed more time, now what if the only way he could survi.ve was from stem cell res.earch?

Read this AWESOME article on new research that shows a compound in plants called apigenin could stop breast cancer cells from becoming resistant to cell death.

You need to stop immediately on the side with the tumor, in case rogue cancer cells make it into your daughter's body, and then gradually stop on the other side.»

«On the other hand, if we overexpress this enzyme in prostate cancer cells, we found increased bone metastasis in mice.»

The lab that I work in is primarily interested in understanding how and why certain cancers are more likely to spread to the skeleton, and my personal project has focused on uncovering new mechanisms that the cancer cells use to communicate with other cells in the bone.

Chronic cigarette smoke exposure, as noted in many human cancers, tends to block these cell maturation genes from properly turning on, says Baylin.

The study, led by Dr Len Stephens and Dr Phill Hawkins and published today in the journal Molecular Cell, reveals why loss of the PTEN gene has such an impact on many people with prostate cancer, as well as in some breast cancers.

Current treatments are based on the bulk, brute removal of cells — but miss even a few, and evolution will see to it that the cancer returns in a new, often more resistant, form.

The findings, published in Proceedings of the National Academy of Sciences (PNAS), define a mechanism in which the oncogenes turn on a protein called RSK2 that is required for cancer cells to move.

«In addition, changes in how the genes are expressed (turned on or off) could be used in the future to predict how and when the cancer cells will spread to other parts of the body and how fast they will grow.&raquIn addition, changes in how the genes are expressed (turned on or off) could be used in the future to predict how and when the cancer cells will spread to other parts of the body and how fast they will grow.&raquin how the genes are expressed (turned on or off) could be used in the future to predict how and when the cancer cells will spread to other parts of the body and how fast they will grow.&raquin the future to predict how and when the cancer cells will spread to other parts of the body and how fast they will grow.»

On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.

«The fine particles of this drug allow for it to be released slowly and stay in the abdomen,» said Katherine Roby, Ph.D., research associate professor in the Department of Anatomy and Cell Biology at KU Medical Cancer, who started her pre-clinical work on Nanotax more than a decade ago.

In a report on the research published March 27 in Nature Genetics, the team says the findings also suggest that such epigenetic variability is a major factor in the ability of cancer cells to proliferate, adapt and metastasizIn a report on the research published March 27 in Nature Genetics, the team says the findings also suggest that such epigenetic variability is a major factor in the ability of cancer cells to proliferate, adapt and metastasizin Nature Genetics, the team says the findings also suggest that such epigenetic variability is a major factor in the ability of cancer cells to proliferate, adapt and metastasizin the ability of cancer cells to proliferate, adapt and metastasize.

Moreover, in the aftermath of surgery, the immune system concentrates most of its efforts on healing the surgical wound, lowering its guard against cancer cells.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

«Current therapies in clinical trials are focused on targeting genetic changes in tumors and helping to boost one's immune system to fight the cancer cells.

Fostamatinib's effect on microtubules seems to increase the stabilizing effect of paclitaxel, even in resistant cells, which in turn may prevent cancer cells from proliferating, says Yu Yu, Ph.D., a postdoctoral fellow at the Johns Hopkins University School of Medicine and co-author of the study.

«This model was trained on genetic data from human tumors in The Cancer Genome Atlas and was able to predict response to certain inhibitors that affect cancers with overactive Ras signaling in an encyclopedia of cancer cell lines,» GreeneCancer Genome Atlas and was able to predict response to certain inhibitors that affect cancers with overactive Ras signaling in an encyclopedia of cancer cell lines,» Greenecancer cell lines,» Greene said.

The NB activity in Alberta is far ranging, with such research as self - assembled nanostructures (M. J. Brett), single - cell cancer analysis (L. M. Pilarski), computational modeling (D. Wishart), micro-total analysis systems or lab on a chip (D. J. Harrison), cell identification and manipulation (K. Kaler), and microsystems and medical diagnostics (Backhouse).

The idea to specifically study this group of patients was based on groundbreaking research Garon published in the New England Journal of Medicine last year, which found that among patients who received pembrolizumab, those with PD - L1 expression on at least 50 percent of their cancer cells showed the longest survival and disease control.

Dendritic cells are intelligence - gathering immune cells, gathering information on viruses, bacteria, cancer and fungi to aid the immune system in fighting disease.

«Imagine if we could create circuits that detect defects in cancer cells and then turn on pathways that lead to the death of those cells,» he says.

The protein puts the immune system's brakes on, keeping its T cells from recognizing and attacking cancer cells, said Dr. Antoni Ribas, the study's principal investigator and a professor of medicine in the division of hematology - oncology at the David Geffen School of Medicine at UCLA.

The study, published April 4 in the journal The Lancet Oncology, focused on non-small cell lung cancer, which is the most common form of lung cancer.

In a head - to - head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous - non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

Finally, we are in a winning position in the war against cancer thanks to new treatments based on modified immune cells

In this study, the SIgN team discovered for the first time that the integrity of p53 affects the production of a special cell surface protein called Major Histocompatibility Complex (MHC) class I. MHC class I molecules on the cancer cell surface serve as targets for the immune system.

The scientists hope their findings on cell migration in zebrafish will open up new perspectives for research on proteins that control metastasis and thus the malignancy of cancer.

In the early 1990s, in vitro tests on cancer cells by Lane and his colleagues hinted that some compounds could restore mutant p53's normal functioIn the early 1990s, in vitro tests on cancer cells by Lane and his colleagues hinted that some compounds could restore mutant p53's normal functioin vitro tests on cancer cells by Lane and his colleagues hinted that some compounds could restore mutant p53's normal function.

In order to find out how and why ovarian cancer cells grow and take on such lethal characteristics, Dr. Shepherd and his team grow the cancer cells in 3D structures, called «spheroids» — the same way the cancer cells grow in patientIn order to find out how and why ovarian cancer cells grow and take on such lethal characteristics, Dr. Shepherd and his team grow the cancer cells in 3D structures, called «spheroids» — the same way the cancer cells grow in patientin 3D structures, called «spheroids» — the same way the cancer cells grow in patientin patients.

The engineered cells will circulate and, the team hopes, home in on the cancer, says Lu.

Prostate cancer risk groups are assigned based on the prostate biopsy results, which include the Gleason score (GS)-- an indication of how aggressively the tumor cells may behave — and the prostate specific antigen (PSA) level in the patient's blood at the time of diagnosis.

This is how treatments based on a type of white blood cell called T - cells are curing some cancers, rather than just slowing their advance (see «Cancer meets its nemesis in reprogrammed blood cells «-RRB-.

For some cancer patients, viruses engineered to zero in on tumor cells work like a wonder drug.

Bloch's colleagues at the National Institute of Environmental Health Sciences tested the oils in gene expression studies on lab - grown human breast cancer cells and found that they could mimic estrogens, the primary female sex hormones, and inhibit androgens, the primary male sex hormones.

In many very invasive forms of breast cancer, the cells have too much of the receptor HER2 on their surface.

Lab testing showed that the plant - made virus particles, which naturally bind to receptors on cancer cells, were taken in by human breast cancer cells.